SIGA Technologies

SIGA

Market cap $421M

SIGA Technologies, Inc. ( SIGA ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Diem Nguyen - CEO & Director Daniel Luckshire - Executive VP, CFO & Secretary Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Presentation Operator Welcome to the SIGA Business Update Call. Before we turn the call over to SIGA management, please note that any forward-looking statements made during this call are based on management's current expectations and observations and are subject to risks and uncertainties that could cause actual results to differ from the forward-looking statements.

NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and nine months ended September 30, 2025. “We continue to advance SIGA's key priorities while generating $86 million in product revenues and $33 million in pre-tax operating income for the first nine months of 2025," stated Diem Nguyen, Chief Executive Officer.

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, November 6, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.

Healthcare stocks haven't moved since the April lows. As contrarian investors, this neglect piques our interest.

SIGA's investment thesis is overwhelmingly tied to the renewal of the BARDA contract, which remains highly uncertain due to political and budgetary risks. Recent revenue growth and a strong balance sheet are positives, but the company faces label risk in the EU and heavy reliance on U.S. government funding. Potential catalysts include TPOXX label expansion for post-exposure prophylaxis and a new BARDA contract, while EU label changes and U.S. defunding are key risks.

SIGA (SIGA) Q2 Revenue Soars 272%

SIGA Technologies, Inc. (NASDAQ:SIGA ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Daniel J. Luckshire - Executive VP, CFO & Secretary Diem Nguyen - CEO & Director Conference Call Participants Jyoti Prakash - Edison Investment Research Limited Operator Welcome to the SIGA Business Update Call.

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and six months ended June 30, 2025.

The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields.

NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer.